A phase 2 study of ZK219477 [sagopilone] (ZK-EPO) in patients with breast cancer and brain metastases.

Trial Profile

A phase 2 study of ZK219477 [sagopilone] (ZK-EPO) in patients with breast cancer and brain metastases.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2013

At a glance

  • Drugs Sagopilone (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Mar 2013 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Planned number of patients changed from 37 to 49 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top